The decision to return the program to AVEO is because portfolio prioritization. .. AVEO regains global privileges for advancement, commercialization of AV-299 anti-HGF antibody candidate AVEO Pharmaceuticals, Inc. , a biopharmaceutical firm focused on discovering, developing and commercializing cancer therapeutics, today announced that AVEO offers regained worldwide privileges from Merck to build up and commercialize AV-299 , its anti-hepatocyte growth factor antibody candidate. In 2010 June, AVEO initiated a Phase 2 clinical trial analyzing AV-299 in combination with gefitinib versus gefitinib monotherapy in individuals with non-small cell lung cancer . With the Phase 2 trial initiation, AVEO received an $8.5 million milestone payment from Merck under the terms of the permit agreement.It has the potential to go critical care practice forwards quickly.’ Related StoriesUAB study aims to supply improved care related to reproductive health of females with CFHealthcare technology cultural event of the year opens entriesNew UCLA study talks about primary care medical home in reducing childrens' repeat visits to hospitals For the next 16 months, teams of four nurses from each hospital will continue to work with CSI faculty, an internal mentor and their chief nursing officer to identify issues related to their existing individual care responsibilities. Teams will develop and implement unit-based projects then, resulting in quantifiable improvements in patient outcomes and decreases in medical center expenses.